Information Provided By:
Fly News Breaks for August 11, 2017
Aug 11, 2017 | 09:25 EDT
Craig-Hallum analyst Matt Hewitt said he does not believe the FDA "update" letter regarding potential risks with liquid-filled intragastric balloons will have an adverse impact on future utilization of Apollo Endosurgery's Orbera device and he thinks the selloff related to its publication presents an opportunity for investors. Hewitt keeps a Buy rating and $11 price target on Apollo Endosurgery shares.
News For APEN From the Last 2 Days
There are no results for your query APEN
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.